Sorin Group acquires CalMed for $14M

Tuesday, July 3, 2012 10:14 AM

Sorin Group, a global medical device company with a focus on cardiovascular diseases, has acquired California Medical Laboratories (CalMed), a manufacturer of high quality cardiovascular cannulae, for $14 million.

The acquisition represents an ideal complement to Sorin existing cannulae offering and to the recent acquisition of the Estech minimally invasive cannulae product line.

“We believe that building on CalMed’s rich product offering and pipeline and leveraging on Sorin’s global sales network will drive to a significant adoption of these products by cardiac surgeons worldwide,” said Mehmet Bicakci, President and CEO of CalMed.

CalMed develops, manufactures and distributes a complete range of cannulae, catheters and accessories for cardiac surgery. Available in more than 45 countries worldwide, CalMed products are approved by the FDA and are CE marked for commercialization in the E.U. In the 2011 FY, CalMed reported revenues of almost $8 million.

“This deal confirms Sorin Group’s commitment to further strengthen our presence in the cannulae segment and consolidate our relationship with cardiac surgeons and clinical perfusionists worldwide,” said Michel Darnaud, president of cardiopulmonary business unit and intercontinental, Sorin Group.

Sorin will continue to develop new products and make selective, strategic acquisitions to enhance its worldwide leadership position in the cardiopulmonary business.

Share:          
CWWeekly

July 27

AB Science warned about putting study volunteers in danger

FDA, Google unite to detect search-data adverse events

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

Integrated research partnerships build momentum
Research function provides infrastructure, leverages large pool of health systems' patients and data

'Right to Try' laws challenge clinical trial process
20 states pass, 20 more pending allowing access to study drugs without FDA and IRB approval

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

TransCelerate Biopharma turns three
High-profile consortium has made inroads fixing wasteful practices, but it still has more work ahead

Pharma industry improves its tarnished reputation
Delivering innovation, social responsibility will help rebuild trust

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs